Skip to contentS
Sonoma Pharmaceuticals, Inc.
S
SNOASonoma Pharmaceuticals, Inc. Q1 2022 · 10-Q
Revenue$3.68M$3.68M−36.1% vs Q1 2021 Net Income-$1.10M-$1.10MN/M vs Q1 2021 EPS Diluted-$0.52-$0.52N/M vs Q1 2021 Gross Profit$1,453,000−35.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sonoma Pharmaceuticals, Inc. · CIK 1367083 · Engraved from SEC EDGAR
Operating Cash Flow-$1,223,000N/M Free Cash Flowderived-$1,272,000N/M Margins · derivedGross margin39.4%+0.3 pt vs Q1 2021
Operating margin-24.5%−13.0 pt vs Q1 2021
Net margin-29.8%−34.0 pt vs Q1 2021
ended Jun 30, 2021 · filed Aug 16, 2021 · 47 d after period end